VXRT News and Press, Vaxart Inc. From 06/07/21

SOUTH SAN FRANCISCO, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that its executive officers, Andrei Floroiu, CEO,...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vaxart  (NASDAQ: VXRT ) is an intriguing biotech company that is attempting to develop oral vaccines for a number of conditions, including most notably, Covid-19. If you ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s tempting to view Vaxart (NASDAQ: VXRT ) as a company unfortunately one year too late. And it might be an accurate assessment. Though VXRT stock was tied to a compelling need, that is to address the novel c...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors looking for a high-risk, high-reward investment in a vaccine maker should consider buying a small amount of Vaxart (NASDAQ: VXRT ) stock. Source: Ascannio / Shutterstock.com Vaxart has developed a vacc...

The FDA has said yesterday it may turn down emergency use authorizations ((EUA)) for COVID-19 vaccines for the remainder of the pandemic unless the developers have not already begun discussion with the regulator, Reuters reported.Under a EUA, the FDA facilitates the availability and use ...

These Current & Former Penny Stocks Are Making Their Mark In 2021 Penny stocks have been a big focus for retail traders over the last few years. In fact, if you look at any of the top small-cap stock ETFs, the trend is clear right now. Since the depths of the pandemic drop, the Russ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of clinical-stage biotech company Vaxart (NASDAQ: VXRT ) have cooled off considerably after gaining about 1,500% last year. However, it’s still plodding along in developing its oral Coronavirus vaccine c...

The coronavirus vaccine market is only a few months old, but it is already worth well over $1 billion. And while companies such as Moderna and Pfizer are currently leaders in this space, others are working to throw their hats into the ring. Two of them are Vaxart (NASDAQ: VXRT...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vaxart (NASDAQ: VXRT ) tried to produce a Covid-19 vaccine that could be taken orally as a pill, but it failed. As a result, VXRT stock is probably headed down 85% to its cash per share level, or about $1.00. Sour...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Is now the time to take a look at speculative Covid-19 play Vaxart (NASDAQ: VXRT ) stock? The clinical-stage biotech name has been at work on an oral coronavirus vaccine since before Covid-19 was declared a pandemic ...